Twin Cities Pain Clinic Integrates New Spinal Cord Stimulation Device; Provides Tailored, Opioid-Free Relief to Multiple Pain Areas and Options for Evolving Pain Conditions

The new Proclaim[™] Plus SCS system by Abbott offers the next generation of stimulation therapy, giving physicians the ability to adjust dosage and treat multi-site and evolving pain

EDINA, Minn., Oct. 10, 2022 – Twin Cities Pain Clinic announced it is integrating the new Proclaim[™] Plus spinal cord stimulation (SCS) system featuring FlexBurst360[™] therapy as a treatment option for chronic pain patients.

Recently approved by the U.S. Food and Drug Administration, the next generation of Abbott's proprietary BurstDR[™] stimulation, FlexBurst360 therapy offers pain coverage across up to six areas of the trunk and/or limbs and enables adaptable programming that can be adjusted as a person's therapeutic needs evolve.

Twin Cities Pain Clinic is a spinal cord stimulation (SCS) center of excellence. Their four physicians are chronic pain experts, each highly specialized in spinal cord stimulation therapy. They collectively complete hundreds of SCS implant procedures every year at the clinic's two metro are outpatient surgery centers.

Designed to fit within a person's life, the Proclaim Plus SCS system is recharge-free with a battery that can last up to 10 years.[^] The system can seamlessly integrate with Abbott's NeuroSphere[™] Virtual Clinic connected care technology, which allows a person to both communicate with a physician through secure in-app video chat and remotely receive stimulation settings in real time, regardless of location.^{*}

BurstDR therapy is Abbott's exclusive stimulation technology that delivers pulses – or bursts – of mild electrical energy to alter pain signals as they travel from the spinal cord to the brain. Clinical studies have shown that BurstDR technology delivers superior pain relief as compared to tonic stimulationⁱ, improves people's day-to-day life, and reduces the emotional suffering[§] associated with pain.ⁱⁱ When compared to standard tonic stimulation technology, which provides a constant tingling sensation felt by the patient, 87% of people preferred BurstDR technology, which provides pain relief in a sub-sensory range not felt by the patient.ⁱⁱⁱ

Using FlexBurst360 therapy on the Proclaim Plus system, physicians can identify the lowest effective dose of stimulation for each patient and adapt it based on evolving pain needs. The

system allows doctors control over multiple independent BurstDR stimulation areas to provide broader pain coverage without overstimulation risk.^{iv}

"The introduction of the Proclaim Plus spinal cord stimulation system is a major step forward for our organization, but for the field of pain medicine as a whole," said Dr. Sherri Haas, Assistant Medical Director of Twin Cities Pain Clinic. "Chronic pain is a complex condition, and a large portion of patients have pain affecting two or more different areas of the body. The ability to treat pain in multiple areas of the body using a single device that does not require recharging makes the Proclaim Plus a uniquely innovative, opioid-free treatment option. Introducing this new device allow us to provide more comprehensive results for many of our patients."

Dr. Haas is a leading authority on spinal cord stimulation therapy. She is regularly invited to be a featured presenter and trainer at national neuromodulation education events and recently became the first female physician in the upper Midwest to implant the new Proclaim Plus SCS device.

The Proclaim Plus system with FlexBurst360 therapy is designed to fit seamlessly within a person's life and therapy settings can be accessed using either a personal mobile device** or through an Abbott-provided mobile device. Patients can use the same device to access Abbott's proprietary NeuroSphere Virtual Clinic, a first-of-its-kind neurostimulation technology^v in the U.S. that allows patients to communicate with physicians, ensure proper functionality of their device, and receive remote adjustments to their therapeutic settings as needed.

* Anywhere with a cellular or Wi-Fi connection and sufficiently charged patient controller.

^Up to 10 years of battery longevity at the lowest program setting: 0.6mA, 500 Ohms, duty cycle 30s on/360s off, single area BurstDR stimulation. Refer to the IFU for additional information.

§ Pain and suffering as measured by visual analog scale

**For a list of compatible devices: <u>https://www.neuromodulation.abbott/us/en/mobile-device-os-</u> <u>compatibility.html</u>

For U.S. important safety information on the Abbott Proclaim Plus with FlexBurst360, visit: <u>https://www.neuromodulation.abbott/us/en/important-safety-info.html</u>

About Twin Cities Pain Clinic

Twin Cities Pain Clinic is a comprehensive pain management organization that has been helping patients achieve relief from chronic pain since 2003. As a leading authority in the field of chronic pain management, our organization is committed to providing every patient with a customized treatment plan consisting of the most advanced and effective therapies to provide optimal outcomes. To learn more or schedule an appointment, go online to **www.twincitiespainclinic.com** or call **(952) 841-2345.**

MEDIA CONTACT Jeffrey Blanchard Marketing Manager Jeffrey.blanchard@tcpain.com (952) 204-3556

###

ⁱⁱ Deer T, Slavin KV, Amirdelfan K, et al. Success Using Neuromodulation With BURST (SUNBURST) Study: Results From a Prospective, Randomized Controlled Trial Using a Novel Burst Waveform. Neuromodulation. 2017.

ⁱ Karri J, Joshi M, Polson G, Tang T, Lee M, Orhurhu V, et al. Spinal Cord Stimulation for Chronic Pain Syndromes: A Review of Considerations in Practice Management. Pain Physician. 2020 Nov;23(6):599-616.

^{III} Deer, T. Randomized, Controlled Trial Assessing Burst Stimulation for Chronic Pain: 2-Year Outcomes from the SUNBURST Study. Presented at NANS 2018.

^{iv} Falowski. Utilizing intraoperative neuromonitoring to program multiple areas of Burst spinal cord stimulation for treatment of chronic pain. Poster presented at ASPN 2022.

^v Abbott. Data on File. MAT-2101330 v1.0.